NYSE:EVMN Evommune Q3 2025 Earnings Results & Report $5.86 -0.19 (-3.06%) Closing price 10/13/2026 03:59 PM EasternExtended Trading$5.89 +0.03 (+0.49%) As of 10/13/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Evommune missed analyst earnings expectations and met on revenue in its Q3 2025 results, released December 11, 2025. The company reported EPS of -$8.07 versus the -$6.58 consensus estimate, while revenue of $10.00 million matched the $10.00 million estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateDecember 11, 2025TimeAfter Market ClosesConference Call4:00 PM ET Evommune EPS ResultsActual EPS-$8.07Consensus EPS -$6.58Beat/MissMissed by -$1.49One Year Ago EPSN/AEPS Beat Rate1 of last 4 quartersEvommune Revenue ResultsActual Revenue$10.00 millionExpected Revenue$10.00 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Evommune Q3 2025 Earnings FAQ Did Evommune beat earnings estimates for Q3 2025? Evommune (NYSE:EVMN) reported earnings of -$8.07 per share for Q3 2025, missing the consensus estimate of -$6.58. The report was announced on Thursday, December 11, 2025. What was Evommune's revenue for Q3 2025? Evommune reported revenue of $10.00 million for Q3 2025, against a consensus estimate of $10.00 million. Evommune Earnings HeadlinesUBS Initiates Coverage on Evommune With Neutral Rating, $8 Price TargetOctober 12 at 3:07 PM | marketscreener.comMEvommune (NYSE:EVMN) versus Cue Biopharma (NASDAQ:CUE) Financial AnalysisOctober 12 at 4:28 AM | americanbankingnews.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December. | Porter & Company (Ad)Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology CongressOctober 1, 2026 | finance.yahoo.comEvommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 CongressSeptember 23, 2026 | marketscreener.comMEvommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a DataSeptember 23, 2026 | tipranks.comSee More Evommune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evommune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evommune and other key companies, straight to your email. Email Address About EvommuneEvommune (NYSE:EVMN) is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company’s research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms. Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders. Its development programs are intended to offer differentiated approaches for patients who do not respond adequately to existing therapies. The company does not currently market an approved commercial product, and its drug candidates remain subject to clinical development and regulatory review. Evommune is headquartered in the United States and works through research, clinical-development and biotechnology partnerships to advance its pipeline.View Evommune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
